Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00422175 | Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312 | PHASE1 | COMPLETED | 63 | — | — | Oct 1, 2006 | Nov 1, 2007 | Nov 29, 2007 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| BAF 312 | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects, 18 to 55 years of age included, and in good health * Female subjects must be either surgically sterilized at least 6 months prior to study participation or post-menopausal (no regular menstrual bleeding for at least 1 years) * Female subjects ...